Dominick Colangelo Sells 24,850 Shares of Vericel Co. (NASDAQ:VCEL) Stock

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 24,850 shares of the business’s stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $41.89, for a total value of $1,040,966.50. Following the transaction, the chief executive officer now directly owns 260,354 shares in the company, valued at $10,906,229.06. This trade represents a 8.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Dominick Colangelo also recently made the following trade(s):

• On Thursday, March 13th, Dominick Colangelo sold 26,592 shares of Vericel stock. The shares were sold at an average price of $45.78, for a total transaction of $1,217,381.76.

Vericel Stock Down 1.6 %

Shares of Vericel stock traded down $0.65 on Friday, hitting $41.25. The stock had a trading volume of 601,585 shares, compared to its average volume of 388,966. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of 687.61 and a beta of 1.61. Vericel Co. has a twelve month low of $37.76 and a twelve month high of $63.00. The business’s 50 day moving average is $49.57 and its two-hundred day moving average is $51.44.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in shares of Vericel by 119.3% during the fourth quarter. Wellington Management Group LLP now owns 1,288,921 shares of the biotechnology company’s stock worth $70,775,000 after buying an additional 701,064 shares in the last quarter. Champlain Investment Partners LLC acquired a new stake in Vericel in the 4th quarter worth about $34,233,000. Raymond James Financial Inc. acquired a new stake in Vericel in the 4th quarter worth about $28,126,000. William Blair Investment Management LLC grew its position in shares of Vericel by 66.3% during the 4th quarter. William Blair Investment Management LLC now owns 1,258,416 shares of the biotechnology company’s stock worth $69,100,000 after purchasing an additional 501,736 shares in the last quarter. Finally, Federated Hermes Inc. grew its position in shares of Vericel by 25.4% during the 4th quarter. Federated Hermes Inc. now owns 1,122,373 shares of the biotechnology company’s stock worth $61,630,000 after purchasing an additional 227,675 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Canaccord Genuity Group increased their price target on shares of Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. Stephens reissued an “overweight” rating and set a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial cut their price objective on Vericel from $61.00 to $51.00 and set a “buy” rating for the company in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Vericel in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $60.86.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.